Stock RVV REVIVE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Market Closed - Canadian Securities Exchange
Other stock markets
 01:23:32 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.03 CAD +20.00% Intraday chart for Revive Therapeutics Ltd. 0.00% 0.00%
Apr. 23 FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID MT
Apr. 23 Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID
MT
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
MT
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
MT
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
MT
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
GL
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
CI
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
MT
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
GL
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
AQ
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
CI
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
MT
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
CI
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
MT
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
GL
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
CI
Revive Therapeutics Provides Corporate Update
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVV Stock
  4. News Revive Therapeutics Ltd.